References
- 1. Kostova I. Platinum complexes as anticancer agents. Recent Pat Anticancer Drug Discov. 2006; 1(1):1-22.
- 2. Alderden RA, Hall MD, Hambley TW. The Discovery and Development of Cisplatin. J Chem Educ. 2006; 83(5): 728-33.10.1021/ed083p728
- 3. Florea АМ, Busselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers. 2011; 3(1): 1351-71.
- 4. Mishra AK, Mishra SB, Manav N, Saluja D, Chandra R, Kaushik NK. Synthesis, characterization, antibacterial and cytotoxic study of platinum(IV) complexes. Bioorg Med Chem. 2006; 14(18): 6333-40.10.1016/j.bmc.2006.05.047
- 5. Mishra AK, Kaushik NK. Synthesis, characterization, cytotoxicity, antibacterial and antifungal evaluation of some new platinum(IV) and palladium(II) complexes of thiodiamines. Eur J Med Chem. 2007; 42(10): 1239-46.
- 6. Wong E, Giandomenico CM. Current status of platinum- based antitumor drugs. Chem Rev. 1999; 99(9): 2451-66.
- 7. Manav N, Mishra AK, Kaushik NK. In vitro antitumour and antibacterial studies of some Pt(IV) dithiocarbamate complexes. Spectrochim Acta A Mol Biomol Spectrosc. 2006; 65(1): 32-5.
- 8. Mishra AK, Mishra SB, Manav N, Kumar R, Chandra R, Saluja D, Kaushik NK. Platinum(IV) thiohydrazide, thiodiamine and thiohydrazone complexes: A spectral, antibacterial and cytotoxic study. Spectrochim Acta A Mol Biomol Spectrosc. 2007; 66(4): 1042-7.
- 9. Hall MD, Mellor HR, Callaghan R, Hambley TW. Basis for design and development of platinum(IV) anticancer complexes. J Med Chem. 2007; 50(15): 3403-11.10.1021/jm070280u
- 10. Shader D, Ahluwalia GS, Grosso D. Method of reducing hair growth employing sulfhydryl active compounds. Unated States Patent. 1995.
- 11. Wiener JH, Kloog Y, Wacheck V, Burkhard J. Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo. J Invest Dermatol. 2003; 120 (1): 1-7.
- 12. Smalley KSM, Eisen TG. Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. Int J Cancer. 2002; 98: 514-22.10.1002/ijc.10213
- 13. Asadi S, Zhang B, Weng Z, Angelidou A, Kempuraj D, Alysandratos KD, Theoharides TC. Luteolin and thiosalicylate inhibit HgCl2 and thimerosal-induced VEGF release from human mast cells. Int J Immunopathol Pharmacol. 2010; 23(4): 1015-20.
- 14. Smith DJ, Yap GP, Kelley JA, Schneider JP. Enhanced stereoselectivity of a Cu(II) complex chiral auxiliary in the synthesis of Fmoc-L-γ-carboxyglutamic acid. J Org Chem. 2011; 76(6):1513-20.
- 15. Radić GP, Glođović VV, Radojević ID, Stefanović OD, Čomić LjR, Ratković ZR, Valkonen A, Rissanen K, Trifunović SR. Synthesis, characterization and antimicrobial activity of palladium(II) complexes with some alkyl derivates of thiosalicylic acids. Crystal structure of bis(S-benzyl-thiosalicylate)-palladium(II) complex, [Pd(S-bz-thiosal)2]. Polyhedron. 2012; 31: 69-76.
- 16. Smith DJ, Yap GP, Kelley JA, Schneider JP. Enhanced stereoselectivity of a Cu(II) complex chiral auxiliary in the synthesis of Fmoc-L-γ-carboxyglutamic acid. J Org Chem. 2011; 76(6): 1513-20.
- 17. Agilent, CrysAlis PRO, Agilent Technologies, Yarnton, Oxfordshire, England (2010)
- 18. (a) Altomare A, Burla MC, Cavalli M, Cascarano G, Giacovazzo C, Gagliardi A, Moliterni AG. Polidori G, Spagna R, Sir97: A New Program For Solving and Refining Crystal Structures, Istituto di Ricerca per lo Sviluppo di Metodologie Cristallografiche CNR, Bari (1997); (b) Altomare A, Burla MC, Cavalli M, Cascarano G, Giacovazzo C, Gagliardi A, Moliterni GG, Polidori G, Spagna R, SIR97: a new tool for crystal structure determination and refinement. J Appl Cryst. 1999; 32: 115-119.
- 19. Sheldrick GM. SHELXS-97 and SHELXL-97. Programs for solution and refinement of crystal structures from diffraction data, University of Gottingen, Germany, 1997, Acta Crystallogr. 2008; A64: 112-22.
- 20. Farrugia LJ, WinGX suite for small-molecule singlecrystal crystallography, University of Glasgow, Scotland, 1998; J Appl Cryst. 1999; 32: 837-8.
- 21. Farrugia LJ. ORTEP-3 for Windows - a version of ORTEP-III with a Graphical User Interface (GUI), University of Glasgow, Scotland, 1997; J.Appl Cryst 1997; 30: 565.
- 22. Spek AL. Structure validation in chemical crystallography. Acta Crystallogr. 2009; D65: 148-55.
- 23. Schoenberg LN, Cooke DW, Liu CF. Nuclear magnetic resonance determination of the absolute configuration of complexes of cobalt(III) with asymmetric tetradentate ligands. Inorg Chem. 1968; 7: 2386-93.10.1021/ic50069a040
- 24. Swaminathan K, Busch DH. The synthesis and infrared absorption spectra of complexes of cobalt with pentadentate propylenediaminetetraacetic acid. J Inorg Nucl Chem. 1961; 20(1): 159-63.10.1016/0022-1902(61)80475-2
- 25. Nakamoto К. Infrared spectra of the inorganic and coordination compounds. New York: Willey; 1963.
- 26. Silverstein RM, Bassler CG, Morril TC. Spectrometric identification of organic compounds, 3rd ed. Wiley International Edition, 1974. p.113.
- 27. Nakamoto K. Infrared Spectra of Inorganic and Coordination Compounds, Wiley, New York, 1963. p. 206.
- 28. Sim GA, Monteath Robertson J, Goodwin TH. The crystal and molecule structure of benzoic acid, Acta Cryst. 1955; 8: 157-64.
- 29. Jones RE, Templeton DH. The crystal structure of acetic acid. Acta Cryst. 1958; 11(7): 484-8.
- 30. Wright WB, King GSD. The crystal structure of nicotinic acid. Acta Cryst. 1953; 6: 305-17.
- 31. Van Schalkwyk TGD. The crystal structure of phthalic acid. Acta Cryst. 1954; 7(11): 775.
- 32. Cohran W. The crystal and molecular structure of salicylic acid. Acta Cryst. 1953; 6: 260-268.